THE IMMUNOMODULATORY POTENTIALS OF INTERLEUKIN-27 IN AIRWAY ALLERGIES
AND COVID-19
Abstract
Allergic airway disorders such as asthma and allergic rhinitis are
mainly caused by inhaled allergen-induced improper activation and
responses of immune- and non-immune cells. One important response is the
production of IL-27 by macrophages and dendritic cells (DCs) during the
early stage of airway allergies. IL-27 exerts powerful modulatory
influences on the cells of innate immunity [e.g., neutrophils,
eosinophils, mast cells, monocytes, macrophages, dendritic cells (DCs),
innate lymphoid cells (ILCs), natural killer (NK) cells and
NKT-cells)] and adaptive immunity (e.g. Th1-, Th2-, Th9-, Th17-,
regulatory T-, CD8+ cytotoxic T- and B-cells). The IL-27-mediated
signaling pathways may be modulated to attenuate asthma and allergic
rhinitis. In this review, a comprehensive discussion concerning the
roles carried out by IL-27 in asthma and allergic rhinitis was provided,
while evidences are presented favouring the use of IL-27 in the
treatment of airway allergies.